GlassScriptPhysician profile
Venkatesh K Nadar
NPI 1154383826
$47,366.26
in general payments reported to CMS, 2019-2025
59 companies · $2,993 in 2025
The $2,993 reported for 2025 was more than what 88% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $4,835 · 2020: $2,339 · 2021: $3,521 · 2022: $2,638 · 2023: $21K · 2024: $9,695 · 2025: $2,993.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $21K · Food and Beverage: $13K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $20,933.50 |
| Food and Beverage | $13,100.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eli Lilly and Company | $13,122.99 | 2019-2024 | |
| Pfizer INC. | $4,642.03 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $3,183.34 | 2019-2025 | Camzyos, Eliquis |
| Bayer Healthcare Pharmaceuticals INC. | $2,339.78 | 2023-2025 | |
| Alnylam Pharmaceuticals INC. | $2,005.47 | 2024 | |
| Medtronic, INC. | $1,893.86 | 2021-2024 | Venaseal, Symplicity G3, Ffrangio |
| Boehringer Ingelheim International Gmbh | $1,727.85 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,706.20 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $1,630.60 | 2019-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $1,610.89 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $1,601.32 | 2019-2024 | Farxiga |
| Boston Scientific Corporation | $1,526.86 | 2019-2024 | Watchman Flx |
| Amgen INC. | $1,255.80 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $1,094.97 | 2021-2025 | |
| Esperion Therapeutics, INC. | $1,045.18 | 2020-2025 | Nexletol |
Show all 53 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $1,003.71 | 2019-2023 | |
| Surmodics, INC. | $805.66 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $789.79 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| Amarin Pharma, INC. | $551.67 | 2019-2022 | |
| Impulse Dynamics (USA) INC. | $549.44 | 2022-2025 | Optimizer, Optimizer |
| Novo Nordisk INC | $537.11 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Daiichi Sankyo INC. | $306.43 | 2022-2025 | Injectafer |
| Chiesi USA, INC. | $248.06 | 2020-2022 | |
| Lexicon Pharmaceuticals, INC. | $242.17 | 2024 | Inpefa |
| Regeneron Pharmaceuticals, INC. | $208.43 | 2019 | |
| Bridgebio Pharma, INC. | $176.26 | 2025 | Attruby |
| Shockwave Medical, INC | $175.24 | 2023-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Biotronik INC. | $161.89 | 2021-2024 | Biomonitor |
| Kiniksa Pharmaceuticals International, Plc | $142.15 | 2024 | Arcalyst |
| Medtronic Vascular, INC. | $110.84 | 2019-2020 | |
| Kiniksa Pharmaceuticals, LTD. | $108.54 | 2023 | Arcalyst |
| Portola Pharmaceuticals, LLC | $108.10 | 2019 | |
| Janssen Research & Development, LLC | $85.58 | 2024 | |
| Lilly USA, LLC | $83.08 | 2022-2025 | Mounjaro, Zepbound |
| Regeneron Healthcare Solutions, INC. | $75.75 | 2019 | |
| Scpharmaceuticals INC. | $71.55 | 2025 | |
| Baxter Healthcare | $71.23 | 2025 | Hillrom - Cardiac Ambulatory Monitor |
| Cvrx, INC. | $54.68 | 2024 | Barostim Neo System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $32.98 | 2019 | |
| Tactile Systems Technology INC | $30.41 | 2024-2025 | Flexitouch Plus, Nimbl, Entre Plus |
| Heartflow, INC. | $25.49 | 2025 | |
| Cashflow Solutions, LLC | $22.38 | 2025 | Pcd-51 731a (US) - White, Pcd-52 737a (US) White, Lympha Press Optimal Plus(US) Bt |
| Arineta, INC | $22.07 | 2024 | Spotlight |
| Exact Sciences Corporation | $20.47 | 2025 | Cologuard Collection Kit |
| Cleerly, INC. | $20.44 | 2024 | Cleerly Ischemia, Cleerly Labs |
| Medicomp INC | $19.18 | 2024 | Telepatch Cardiac Monitor |
| Janssen Scientific Affairs, LLC | $19.08 | 2022 | |
| Infobionic, INC | $18.67 | 2024 | Mome Device |
| Kestra Medical Technology Services, INC. | $18.21 | 2022 | |
| Abbott Laboratories | $16.67 | 2023 | Agilis Hispro |
| Acist Medical Systems, INC. | $16.44 | 2022 | |
| Inspire Medical Systems, INC. | $15.52 | 2023 | Inspire |
| Bracco Diagnostics INC. | $13.75 | 2024 |
6 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$51,450.60 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Venkatesh Nadar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.